These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

577 related articles for article (PubMed ID: 21212415)

  • 1. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies.
    Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F
    Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy.
    Hawinkels LJ; Garcia de Vinuesa A; Ten Dijke P
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1371-83. PubMed ID: 24053899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiangiogenic therapies targeting the vascular endothelia growth factor signaling system.
    Tie J; Desai J
    Crit Rev Oncog; 2012; 17(1):51-67. PubMed ID: 22471664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function.
    de Vinuesa AG; Bocci M; Pietras K; Ten Dijke P
    Biochem Soc Trans; 2016 Aug; 44(4):1142-9. PubMed ID: 27528762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual targeting of vascular endothelial growth factor and bone morphogenetic protein-9/10 impairs tumor growth through inhibition of angiogenesis.
    Akatsu Y; Yoshimatsu Y; Tomizawa T; Takahashi K; Katsura A; Miyazono K; Watabe T
    Cancer Sci; 2017 Jan; 108(1):151-155. PubMed ID: 28133920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.
    Scharpfenecker M; van Dinther M; Liu Z; van Bezooijen RL; Zhao Q; Pukac L; Löwik CW; ten Dijke P
    J Cell Sci; 2007 Mar; 120(Pt 6):964-72. PubMed ID: 17311849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathways: can activin-like kinase pathway inhibition enhance the limited efficacy of VEGF inhibitors?
    Bhatt RS; Atkins MB
    Clin Cancer Res; 2014 Jun; 20(11):2838-45. PubMed ID: 24714770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors.
    Hawinkels LJ; de Vinuesa AG; Paauwe M; Kruithof-de Julio M; Wiercinska E; Pardali E; Mezzanotte L; Keereweer S; Braumuller TM; Heijkants RC; Jonkers J; Löwik CW; Goumans MJ; ten Hagen TL; ten Dijke P
    Clin Cancer Res; 2016 Jan; 22(1):96-106. PubMed ID: 26373572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.
    Huang SW; Lien JC; Kuo SC; Huang TF
    Carcinogenesis; 2012 May; 33(5):1022-30. PubMed ID: 22436611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complementary actions of dopamine D2 receptor agonist and anti-vegf therapy on tumoral vessel normalization in a transgenic mouse model.
    Chauvet N; Romanò N; Lafont C; Guillou A; Galibert E; Bonnefont X; Le Tissier P; Fedele M; Fusco A; Mollard P; Coutry N
    Int J Cancer; 2017 May; 140(9):2150-2161. PubMed ID: 28152577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Angiogenics: Current Situation and Future Perspectives.
    Zirlik K; Duyster J
    Oncol Res Treat; 2018; 41(4):166-171. PubMed ID: 29562226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metformin inhibits ALK1-mediated angiogenesis via activation of AMPK.
    Ying Y; Ueta T; Jiang S; Lin H; Wang Y; Vavvas D; Wen R; Chen YG; Luo Z
    Oncotarget; 2017 May; 8(20):32794-32806. PubMed ID: 28427181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-human activin receptor-like kinase 1 (ALK1) antibody attenuates bone morphogenetic protein 9 (BMP9)-induced ALK1 signaling and interferes with endothelial cell sprouting.
    van Meeteren LA; Thorikay M; Bergqvist S; Pardali E; Stampino CG; Hu-Lowe D; Goumans MJ; ten Dijke P
    J Biol Chem; 2012 May; 287(22):18551-61. PubMed ID: 22493445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma.
    Wang X; Solban N; Khanna P; Callea M; Song J; Alsop DC; Pearsall RS; Atkins MB; Mier JW; Signoretti S; Alimzhanov M; Kumar R; Bhasin MK; Bhatt RS
    Oncotarget; 2016 Jul; 7(27):41857-41869. PubMed ID: 27248821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinically relevant concentrations of lidocaine inhibit tumor angiogenesis through suppressing VEGF/VEGFR2 signaling.
    Gao J; Hu H; Wang X
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1007-1015. PubMed ID: 30887179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P7170: A Novel Molecule with Unique Profile of mTORC1/C2 and Activin Receptor-like Kinase 1 Inhibition Leading to Antitumor and Antiangiogenic Activity.
    Jalota-Badhwar A; Bhatia DR; Boreddy S; Joshi A; Venkatraman M; Desai N; Chaudhari S; Bose J; Kolla LS; Deore V; Yewalkar N; Kumar S; Sharma R; Damre A; More A; Sharma S; Agarwal VR
    Mol Cancer Ther; 2015 May; 14(5):1095-106. PubMed ID: 25700704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous administration of bevacizumab plus capecitabine, even after acquired resistance to bevacizumab, restored anti-angiogenic and antitumor effect in a human colorectal cancer xenograft model.
    Iwai T; Sugimoto M; Harada S; Yorozu K; Kurasawa M; Yamamoto K
    Oncol Rep; 2016 Aug; 36(2):626-32. PubMed ID: 27350037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.
    Pang X; Yi T; Yi Z; Cho SG; Qu W; Pinkaew D; Fujise K; Liu M
    Cancer Res; 2009 Jan; 69(2):518-25. PubMed ID: 19147565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.